Although M30 and HLA20 likely inhibit other 2OGDD, there appears to be sufficient evidence to merit systematic studies on the roles of PHD1–3 in the brain and their evaluation as AD targets, including by the use of broad spectrum and PHD isoform selective inhibitors. Here, EGLN2 is linked to Alzheimer disease.